Search

Kura Oncology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

12.64 -4.02

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.8

Max

13.34

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5M

-68M

Pardavimai

2.6M

21M

Pelnas, tenkantis vienai akcijai

-0.77

Pelno marža

-327.331

Darbuotojai

260

EBITDA

7M

-66M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+116.08% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

229M

1.1B

Ankstesnė atidarymo kaina

16.66

Ankstesnė uždarymo kaina

12.64

Naujienos nuotaikos

By Acuity

23%

77%

59 / 340 reitingas Healthcare

Kura Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-27 23:46; UTC

Kura Oncology Inc shares are higher in after-market hours, rebounding from earlier declines and staying above recent moving averages. No specific news was identified.

2026-08-26 23:41; UTC

Kura Oncology Inc shares are higher in after-market trading, supported by positive market sentiment despite no specific company news.

2026-08-25 23:06; UTC

News

Kura Oncology Inc. reached a new 52-week high after CEO Troy Wilson acquired 100,000 shares for approximately $1.24 million, reflecting strong market sentiment.

2026-08-24 23:31; UTC

News
Social Media

Kura Oncology shares are higher in after-market hours following CEO Troy Wilson's $1.2 million stock purchase, boosting his ownership to 1.214 million shares.

2026-08-21 22:56; UTC

Kura Oncology shares declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above the 20-day moving average.

2026-08-20 23:16; UTC

Kura Oncology Inc shares are higher in after-market trading, despite no specific news to explain the move. The stock remains above its 20-day moving average.

2026-08-19 19:21; UTC

Social Media

Kura Oncology Inc shares are higher, supported by positive biotechnology sentiment and social media discussions about a recent swing position at $12.57.

2026-08-18 23:06; UTC

Kura Oncology shares are higher in after-market trading, aligning with broader market trends amid rising sovereign bond yields and inflation concerns.

2026-08-17 22:51; UTC

Social Media
News

Kura Oncology shares rose in after-market trading after CEO Troy Wilson's $1.11 million stock purchase and positive earnings report highlighting $9.1 million in revenue.

2026-08-14 22:01; UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains above its 20-day moving average.

2026-08-13 23:52; UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

2026-08-12 23:01; UTC

News
Social Media

Kura Oncology reported second-quarter revenue of $20.87 million, driven by a 57% increase in net product revenue for KOMZIFTI, shares higher in after-market hours.

2026-08-10 19:43; UTC

Event
News

Kura Oncology Inc shares rise as the company highlights ziftomenib's preclinical development in a *Blood* publication, enhancing its positioning in acute myeloid leukemia treatment.

2026-08-07 23:36; UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

2026-08-06 21:02; UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

2026-08-05 19:26; UTC

News

Kura Oncology Inc shares are lower today amid ongoing market volatility. The company will report second-quarter 2026 results after the market close on August 12.

2026-08-04 19:36; UTC

Kura Oncology Inc shares are higher today, continuing an upward trend since Monday. Broader market reactions follow a decline in U.S. core factory orders.

2026-08-03 23:01; UTC

Kura Oncology Inc. shares are higher in after-market trading, reflecting notable gains since Monday's close, despite no specific news to explain the increase.

2026-07-31 21:01; UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable rise since Friday's close despite remaining below the 20-day moving average.

2026-07-30 19:49; UTC

Kura Oncology Inc shares are higher Thursday, continuing a recent upward trend despite no specific news. The stock has rebounded from earlier session lows.

2026-07-29 19:22; UTC

Macro Event

Kura Oncology shares are lower, extending a six-session decline amid market volatility following the Federal Reserve's interest rate decision.

2026-07-28 20:03; UTC

Event

Kura Oncology shares are lower despite positive Phase 1a trial results for darlifarnib plus cabozantinib, reflecting broader market pressures.

2026-07-27 20:07; UTC

Social Media
News
Event

Kura Oncology shares are lower as the company reported Phase 1a results from its FIT-001 trial, showing a 33% to 50% response rate.

2026-07-22 22:01; UTC

Kura Oncology Inc. shares are lower in after-market trading, reflecting unusual volatility amid broader market fluctuations from rising crude oil prices and geopolitical tensions.

2026-07-21 19:36; UTC

Kura Oncology shares are higher Tuesday, amid positive market sentiment despite an earlier pullback. The stock remains below its 20-day moving average.

2026-07-20 18:36; UTC

Kura Oncology shares are lower today, pulling back from earlier gains amid a broader market decline linked to rising Treasury yields and geopolitical tensions.

Akcijų palyginimas

Kainos pokytis

Kura Oncology Inc Prognozė

Kainos tikslas

By TipRanks

116.08% į viršų

12 mėnesių prognozė

Vidutinis 28.22 USD  116.08%

Aukščiausias 40 USD

Žemiausias 15 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Kura Oncology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

10

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

59 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat